Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02862912 · ClinicalTrials.gov registry record · Phase 4

Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)

A Phase 4 study of Adverse Reaction to Spinal Anesthetic and Maternal Care for Cervical Incompetence, sponsored by Columbia University.

Completed
Registry status
Phase 4
Development phase
43
Enrollment target
1
Study location

NCT02862912 is a Phase 4 study of Adverse Reaction to Spinal Anesthetic and Maternal Care for Cervical Incompetence that has completed, run by Columbia University. The registered enrollment target is 43 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02862912, a Phase 4 study of Adverse Reaction to Spinal Anesthetic and Maternal Care for Cervical Incompetence, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 4
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine whether or not spinal anesthesia with the local anesthetic drug, chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in faster discharge from the post-anesthesia care unit after surgery.

Interventions

  • DRUG Bupivacaine
  • DRUG Saline
  • DRUG Fentanyl
  • DRUG Chloroprocaine

Study Locations (1)

New York

  • New York Presbyterian Hospital - New York

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2016-11-08
Est. Completion 2020-01-31
Phase Phase 4

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT02862912

The ClinicalTrials.gov registry entry for NCT02862912 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Adverse Reaction to Spinal Anesthetic appearing as the primary indexed condition, and to 4 interventions - of which Bupivacaine is the first listed.

NCT02862912 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02862912 about?

NCT02862912 is a clinical study titled "Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)". This study aims to determine whether or not spinal anesthesia with the local anesthetic drug, chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in faster discharge from the post-anesthesia care unit after surgery.

What is the current status of trial NCT02862912?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2016-11-08. Estimated completion is 2020-01-31.

What conditions does trial NCT02862912 study?

This clinical trial studies the following conditions: Adverse Reaction to Spinal Anesthetic, Maternal Care for Cervical Incompetence.

What interventions are being tested in trial NCT02862912?

The interventions under investigation include: Bupivacaine (DRUG), Saline (DRUG), Fentanyl (DRUG), Chloroprocaine (DRUG).

Who is sponsoring clinical trial NCT02862912?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02862912 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.